Skip to content
lifestyle.mediatrainingforceos.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Click Therapeutics
FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms
October 5, 2026
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
April 9, 2026